Regentis Biomaterials Ltd. RGNT Archives

TuesdayJul 07, 2026 9:45 am

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration. Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows. With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions. What begins as a localized cartilage defect can ultimately evolve into a significant…

ThursdayJun 04, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Humanitas collaboration supports Regentis' physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution. Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones. Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve…

WednesdayMay 27, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’

GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U.S., offering a single-step procedure that simplifies treatment and integrates into standard surgical workflows. Clinical data show ~100% greater pain improvement versus microfracture, with durable outcomes and MRI-confirmed regeneration of near-native cartilage. A single ~10-minute procedure with ~2-week recovery and lower costs versus cell-based therapies supports strong adoption across surgeons, payers, and patients. The product targets an estimated ~$3 billion U.S. market with ~470,000 annual cases and no comparable ready-to-use competitor. Advancing through a pivotal Phase III trial with CE Mark approval in Europe, the…

FridayMay 22, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair

Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market Regentis' GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis' preparation for commercial scale-up as clinical and regulatory milestones approach Knee cartilage damage remains one of the most…

ThursdayApr 16, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Commercial Strategy Through Humanitas Collaboration

Regentis Biomaterials (NYSE American: RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy, to support expanding clinical activities and commercial strategy for GelrinC(R) in Europe, where the product has CE Mark approval for knee cartilage repair. The collaboration includes Prof. Elizaveta Kon, an internationally recognized expert in cartilage regeneration and orthopedic innovation, who is expected to help lead development of Regentis’ European Centers of Excellence network, supporting surgeon education, clinical expertise and broader adoption of GelrinC(R) as the company advances commercialization. To view the full press release, visit https://ibn.fm/j7jt0 About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative…

TuesdayMar 17, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC(R) Manufacturing With New Solvent-Free Production Process

Regentis Biomaterials (NYSE American: RGNT) announced the development of a new proprietary solvent-free manufacturing process for GelrinC(R), its off-the-shelf hydrogel implant for treating focal articular knee cartilage injuries, that more than quadruples production yield per batch. The company said the new process is designed to improve production economics and gross margins ahead of GelrinC(R)’s planned European commercial launch later this year, while patent filings for the manufacturing innovation have already been granted in India, China and Israel, with U.S. approval pending. To view the full press release, visit https://ibn.fm/HYySr About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company…

TuesdayFeb 24, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports 2025 Financial Results and Clinical Progress for GelrinC(R)

Regentis Biomaterials (NYSE American: RGNT) reported financial results for the year ended Dec. 31, 2025, and provided a corporate and clinical update highlighting progress in its pivotal Phase III study of GelrinC(R) for knee cartilage repair. The company said its strengthened balance sheet, with more than $7 million in cash following its IPO, is expected to support completion of patient recruitment and treatment in the Phase III trial by mid-2026, while also providing runway to begin commercial marketing efforts for GelrinC(R) in Europe. To view the full press release, visit https://ibn.fm/ewdqz About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative…

ThursdayFeb 19, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Appoints Dr. Galit Reske as Chief Medical Officer

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as chief medical officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy and global clinical operations, including leadership of CartiHeal’s IDE pivotal study for the Agili-C(TM) cartilage repair implant and support of the product’s U.S. FDA approval in 2022 prior to CartiHeal’s acquisition by Smith+Nephew in 2023. To view the full press release, visit https://ibn.fm/6kjsX About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore…

TuesdayFeb 17, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Clinical Network to Support GelrinC(R) Commercial Strategy

Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its European clinical site network into new markets, including Italy and Eastern Europe, to support ongoing clinical programs and the commercial strategy for GelrinC(R), which has received CE Mark approval for knee cartilage repair. The expanded network includes leading academic and regional medical centers across Italy, Germany, Serbia, Slovenia and Romania, strengthening the company’s engagement with orthopedic surgeons and centers of excellence as it advances broader clinical adoption and evaluates commercial partnership opportunities in Europe. To view the full press release, visit https://ibn.fm/ala7S About Regentis Biomaterials Regentis Biomaterials Ltd is a…

WednesdayFeb 04, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Appoints Ori Gon as CFO and Chief Business Officer

Regentis Biomaterials (NYSE American: RGNT) announced the appointment of Ori Gon as chief financial officer and chief business officer, effective immediately. Gon will oversee the company’s commercial and business development initiatives, as well as financial strategy, planning and reporting, as Regentis advances GelrinC(R) toward commercialization in Europe following CE Mark approval and continues its pivotal Phase III FDA clinical trial in the United States. To view the full press release, visit https://ibn.fm/E8WA4 About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an…

Site Search

Company Search

Tag: Regentis Biomaterials Ltd. RGNT